Oval MedicalOval Medical Technologies is developing next-generation autoinjectors including an ultra-portable epinephrine injector. The pictures on their website look like this device will be a great alternative to current epinephrine injectors, it being so much smaller. My feeling is that it would be less scary to use for many who might be needle shy, and that many teens will be more willing to carry it being a smaller design.

- At 93mm x 29.75mm x 16mm, the slimline Oval Medical device easily fits in one hand
- Currently focused on addressing regulatory trials followed by a product launch in about 2019 (UK)

Elevator PitchWindGap Medical
"WindGap Medical’s patient and clinician surveys show that the EpiPen is bulky and awkward to carry, especially for children. It has tight temperature storage requirements of 68-77°F and will rapidly degrade outside of that range. Through patent-pending microfluidics and miniaturization, our product is as small as a USB drive, intuitive to use, and extends the storage temperature range out to 32-105°F."

EmeradeEmerade Emerade is an adrenaline auto-injector used for the emergency treatment of severe acute allergic reactions (anaphylaxis) to foods, medicines or insect stings. It can also be used for exercise induced anaphylaxis. If you experience anaphylaxis, use your Emerade immediately. Emerade is a Prescription only Medicine

The EpiBraclet
Less is known about this, I'm curious who makes it, what stage of testing it is in, and IF it is still in development. It does have teen appeal but the design is so different from current injecting epinephrine designs, I am less enthusiastic about this product.

G2B Pharma
Product Focus:
"Our primary product candidate, G2B011, is a nasal spray formulation of epinephrine for the treatment of anaphylaxis. Anaphylaxis is a severe and life-threatening allergic reaction that affects tens of millions of people worldwide. Common causes of anaphylactic reactions include food allergies and bee stings. Epinephrine is the gold standard for treatment of anaphylaxis and is currently provided for self-administration by injection. The company believes that nasal administration offers an effective and more patient-friendly delivery route for this life-saving medication".

Summary:
Even with new auto injector designs in trail and testing phases, most don't expect these to reach the market for years. If they are fairly priced the end of EpiPen monopoly will hopefully bring prices down for all epinephrine injectors.

FDA Rejections:
In March, generics giant Teva Pharmaceuticals told investors that its generic version of EpiPen was rejected by the FDA, and that it wouldn't be able to launch the generic until at least 2017. Adamis Pharmaceuticals reported a similar rejection from the FDA for its EpiPen generic in June.
Source